$1.91 Billion is the total value of NEA Management Company, LLC's 50 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
RARX | RA PHARMACEUTICALS INC | $294,724,000 | +2.3% | 6,138,797 | 0.0% | 15.40% | +13.0% | |
OYST | OYSTER POINT PHARMA INC | $207,385,000 | +43.2% | 5,925,287 | 0.0% | 10.84% | +58.2% | |
SPT | SPROUT SOCIAL INC | $144,375,000 | -0.6% | 9,046,080 | 0.0% | 7.54% | +9.9% | |
ALLK | ALLAKOS INC | $100,912,000 | -53.3% | 2,268,188 | 0.0% | 5.27% | -48.4% | |
NET | CLOUDFLARE INC | $95,314,000 | +33.8% | 4,059,376 | 0.0% | 4.98% | +47.8% | |
ARDX | ARDELYX INC | $91,728,000 | -24.2% | 16,135,047 | 0.0% | 4.79% | -16.3% | |
CRSP | CRISPR THERAPEUTICS AGnamen akt | $88,666,000 | -30.4% | 2,090,678 | 0.0% | 4.63% | -23.1% | |
AUPH | AURINIA PHARMACEUTICALS INC | $75,056,000 | -28.4% | 5,172,683 | 0.0% | 3.92% | -20.9% | |
RYTM | RHYTHM PHARMACEUTICALS INC | $74,765,000 | -33.7% | 4,912,306 | 0.0% | 3.91% | -26.8% | |
MRSN | MERSANA THERAPEUTICS INC | $69,748,000 | +1.7% | 11,963,649 | 0.0% | 3.64% | +12.4% | |
EPZM | EPIZYME INC | $67,896,000 | -37.0% | 4,377,518 | 0.0% | 3.55% | -30.3% | |
MIRM | MIRUM PHARMACEUTICALS INC | $58,629,000 | -42.9% | 4,187,801 | 0.0% | 3.06% | -36.9% | |
GRTX | GALERA THERAPEUTICS INC | $41,448,000 | -27.8% | 4,362,986 | 0.0% | 2.17% | -20.2% | |
PHAS | PHASEBIO PHARMACEUTICALS INC | $21,991,000 | -45.8% | 6,643,704 | 0.0% | 1.15% | -40.2% | |
GLYC | GLYCOMIMETICS INC | $20,723,000 | -56.9% | 9,089,041 | 0.0% | 1.08% | -52.4% | |
TRVI | TREVI THERAPEUTICS INC | $14,612,000 | -12.3% | 4,441,360 | 0.0% | 0.76% | -3.2% | |
MEIP | MEI PHARMA INC | $13,738,000 | -35.1% | 8,533,072 | 0.0% | 0.72% | -28.3% | |
LQDA | LIQUIDIA TECHNOLOGIES INC | $11,709,000 | +10.0% | 2,486,062 | 0.0% | 0.61% | +21.7% | |
XENE | XENON PHARMACEUTICALS INC | $11,250,000 | -13.5% | 992,107 | 0.0% | 0.59% | -4.4% | |
OBSV | OBSEVA SA | $11,054,000 | -36.9% | 4,586,563 | 0.0% | 0.58% | -30.3% | |
AFMD | AFFIMED NV | $9,680,000 | -42.3% | 6,126,488 | 0.0% | 0.51% | -36.3% | |
MRKR | MARKER THERAPEUTICS INC | $9,500,000 | -34.0% | 5,000,000 | 0.0% | 0.50% | -27.2% | |
MLND | MILLENDO THERAPEUTICS INC | $9,329,000 | -21.7% | 1,766,779 | 0.0% | 0.49% | -13.5% | |
SBBP | STRONGBRIDGE BIOPHARMA PLC | $7,827,000 | -9.7% | 4,141,308 | 0.0% | 0.41% | -0.2% | |
SYBX | SYNLOGIC INC | $7,275,000 | -33.3% | 4,229,410 | 0.0% | 0.38% | -26.4% | |
BE | BLOOM ENERGY CORP | $6,973,000 | -30.0% | 1,333,333 | 0.0% | 0.36% | -22.7% | |
SURF | SURFACE ONCOLOGY INC | $6,199,000 | -0.5% | 3,315,149 | 0.0% | 0.32% | +9.8% | |
RIGL | RIGEL PHARMACEUTICALS INC | $5,059,000 | -27.1% | 3,243,150 | 0.0% | 0.26% | -19.5% | |
VRNA | VERONA PHARMA PLCads | $5,025,000 | -28.3% | 1,219,674 | 0.0% | 0.26% | -20.8% | |
LXRX | LEXICON PHARMACEUTICALS INC | $4,646,000 | -53.0% | 2,382,286 | 0.0% | 0.24% | -48.0% | |
DZSI | DASAN ZHONE SOLUTIONS INC | $4,007,000 | -52.7% | 956,255 | 0.0% | 0.21% | -47.9% | |
ERYP | ERYTECH PHARMA SAadr | $3,338,000 | -27.5% | 625,000 | 0.0% | 0.17% | -20.2% | |
XFOR | X4 PHARMACEUTICALS INC | $3,333,000 | -6.6% | 333,333 | 0.0% | 0.17% | +3.0% | |
TRVN | TREVENA INC | $2,161,000 | -32.6% | 3,811,691 | 0.0% | 0.11% | -25.7% | |
RGLS | REGULUS THERAPEUTICS INC | $946,000 | -48.2% | 2,052,455 | 0.0% | 0.05% | -43.0% | |
AKTX | AKARI THERAPEUTICS PLCadr | $656,000 | -17.1% | 452,167 | 0.0% | 0.03% | -8.1% | |
SNSS | SUNESIS PHARMACEUTICALS INC | $539,000 | +23.1% | 1,298,274 | 0.0% | 0.03% | +33.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-06
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
TREVENA INC | 31 | Q3 2021 | 3.3% |
AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
ARDELYX INC | 29 | Q3 2021 | 11.9% |
RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-11 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-10 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
13F-HR | 2021-11-12 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.